Neumora Therapeutics, Inc. (NMRA)
(Delayed Data from NSDQ)
$11.55 USD
+0.79 (7.34%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $11.57 +0.02 (0.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Neumora Therapeutics, Inc. (NMRA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$22.83 | $29.00 | $18.00 | 121.44% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Neumora Therapeutics, Inc. comes to $22.83. The forecasts range from a low of $18.00 to a high of $29.00. The average price target represents an increase of 121.44% from the last closing price of $10.31.
Analyst Price Targets (6 )
Broker Rating
Neumora Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.17 a month ago based on six recommendations.
Of the seven recommendations deriving the current ABR, six are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 85.71% and 14.29% of all recommendations. A month ago, Strong Buy made up 83.33%, while Buy represented 16.67%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/NMRA.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 5 | 5 | 5 | 5 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.14 | 1.17 | 1.17 | 1.17 | 1.17 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/8/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Not Available | Strong Buy |
6/17/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
4/15/2024 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
2/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
10/10/2023 | Guggenheim Securities | Yatin Suneja | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.14 |
ABR (Last week) | 1.17 |
# of Recs in ABR | 7 |
Average Target Price | $22.83 |
LT Growth Rate | 31.60% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 70 of 252 |
Current Quarter EPS Est: | -0.37 |